dc.creatorVersiani, M.
dc.creatorAmrein, R.
dc.creatorStabl, M.
dc.creatorMagistris,
dc.creatorUdabe, R. Ucha
dc.creatorDa Costa, Delcir A.
dc.creatorNardi, A. E.
dc.creatorVersiani, M.
dc.creatorCapponi, R.
dc.date.accessioned2019-01-29T15:54:59Z
dc.date.available2019-01-29T15:54:59Z
dc.date.created2019-01-29T15:54:59Z
dc.date.issued1997
dc.identifierInternational Clinical Psychopharmacology, Volumen 12, Issue 4, 2018, Pages 183-193
dc.identifier02681315
dc.identifierhttps://repositorio.uchile.cl/handle/2250/162750
dc.description.abstractAn international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R). A total of 315 patients were enrolled and randomly assigned to an 8-week treatment in one of three groups (moclobemide, imipramine and placebo). Patients were male or female outpatients aged between 18 and 65 years meeting DSM III-R criteria for dysthymia, primary type, with late or early onset. Of the patients in each group 85% completed the 8-week treatment period. The percentage of patients who no longer fulfilled DSM-III-R symptom criteria at treatment end-point was significantly higher in the moclobemide (60%) and imipramine (49%) treatment groups than in the placebo group (22%). Differences to placebo were also statistically significant both for moclobemide and for imipramine on the other efficacy variables (i.e. Hamilton Rating Scale f
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceInternational Clinical Psychopharmacology
dc.subjectAntidepressant
dc.subjectChronic disease
dc.subjectChronic minor depression
dc.subjectDepressive disorder
dc.subjectDouble-blind Double depression
dc.subjectDrug treatment
dc.subjectDysthymia
dc.subjectDysthymic disorder
dc.subjectImipramine
dc.subjectMoclobemide
dc.subjectMonoamine oxidase inhibitor
dc.subjectPlacebo
dc.subjectRIMA
dc.subjectTCA
dc.titleMoclobemide and imipramine in chronic depression (dysthymia): An international double-blind, placebo-controlled trial
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución